A Single-arm, Open-label, Multicenter, Phase II Study of AK105 in Patients With Metastatic Nasopharyngeal Carcinoma Who Have Progressed After At Least 2 Prior Lines of Chemotherapy
Latest Information Update: 05 Mar 2025
Price :
$35 *
At a glance
- Drugs Penpulimab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Akeso Biopharma
- 27 Feb 2025 Status changed from active, no longer recruiting to completed.
- 03 Jan 2024 Planned End Date changed from 31 Dec 2023 to 13 Apr 2024.
- 30 Mar 2022 Planned End Date changed from 15 Dec 2020 to 31 Dec 2023.